Skip to main content
Premium Trial:

Request an Annual Quote

French Bioinformatics Firm Ariana Pharma Raises $2.3M in VC Funding

NEW YORK (GenomeWeb News) - Ariana Pharma, a Paris-based provider of drug discovery software tools, said today that it has raised €1.5 million ($2.3 million) through a private placement.
 
Vizille Capital Innovation, a subsidiary of the Crédit Mutuel - CIC bank, was the sole investor in the round and gained a minority stake in the firm. VCI joins Ariana's existing shareholders, the Pasteur Institute and company management.
 
Ariana was founded in 2003 and has been self-funded until now. Its flagship product, called KEM, for knowledge extraction and management, is a data-mining software platform that can “identify relations that link both molecular features and the results of early tests with the risk of adverse events,” the company said.
 
Ariana’s customers include Pfizer, GlaxoSmithKline, Novartis, and Lundbeck.
 
The company said it plans to use the new funding to strengthen its sales and marketing efforts and to add new functionality to KEM that will “enhance its use in clinical trials and drug safety domains, interfacing with current industry standards and providing the new ability to detect early signals.”

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.